Zinaida Good

Zinaida Good, PhD, is a Postdoctoral Fellow and a PICI Scholar who is training under Crystal L. Mackall, MD, and Sylvia K. Plevritis, PhD. Her research is focused on investigating how chimeric antigen receptor (CAR)-expressing T lymphocytes succeed or fail in patients, in order to guide the design of the next generation of engineered cell therapies. Her projects include: (1) identification of CAR T-cell populations that are associated with durable complete response in diffuse large B-cell lymphoma (DLBCL) patients receiving a CD19-targeted therapy Axicabtagene ciloleucel; (2) defining features of successful CAR T-cell clones in DLBCL patients receiving bispecific CD19/CD22-targeted CAR T cells on a Stanford trial; and (3) identifying modulation points to improve CAR T-cell function within the tumor microenvironment in DLBCL and solid tumors. Her goal is to utilize innovative single-cell analysis methods and advanced algorithms to identify promising immunotherapy strategies for patients with cancer.

• 2008: UBC, Vancouver, BC, Canada, B.S., Microbiology & Immunology
• 2012: UBC, Vancouver, BC, Canada, M.S., Microbiology & Immunology
• 2018: Stanford University, Stanford, CA, Ph.D., Computational & Systems Immunology
• Present: Stanford University, Stanford, CA, Postdoc, Systems Biology / Immunology